NTRA - Natera: This Molecular Diagnostic Player Is A Solid Pick In April 2020
Natera (NTRA) has emerged as a rapidly growing company with seven commercialized molecular diagnostic tests targeting key markets of reproductive health, organ transplantation, and oncology. The company enjoys a leadership position in the reproductive health segment, which is almost entirely COVID-19 resilient in the long run. The transplant surveillance tests and oncology tests can also be not deferred for too long since many of the targeted conditions are imminent and rapidly progressive. The market also seems to have realized this about the company.
Hence, while the stock had tanked from $33.29 on January